Business Wire

EnTrust Global Completes Acquisition of Maas Capital From ABN AMRO

Share

The Blue Ocean strategy managed by EnTrust Global (“EnTrust”), a leading alternative asset management firm, announced today that it has completed the acquisition of Maas Capital Shipping B.V. from ABN AMRO. Since its inception in the late 1990s, the Maas Capital platform has deployed close to $1.0 billion in equity maritime investments and is currently one of the world’s leading institutional shipping equity investors. The acquired portfolio includes a diversified portfolio of 15 equity joint venture investments, consisting of a fleet of 76 high-quality vessels within the product/chemical tanker, dry bulk, LPG, container, and offshore services segments. In addition, the portfolio includes an equity stake in a growing intermodal business which leases out container boxes. The acquisition is the latest expansion of EnTrust’s maritime finance strategy, Blue Ocean, which is part of the firm’s broader maritime-focused Blue Ocean Group.

As part of the transaction, EnTrust has engaged six members of the Maas Capital team led by Mark Ras, who will continue to be involved with the management of the portfolio and to source additional growth opportunities for EnTrust.

“The completion of the Maas Capital portfolio acquisition is another step in our expansion into the equity investment space, and something we view as a significant asset for the Blue Ocean strategy,” said Svein Engh, Senior Managing Director of EnTrust Global and Portfolio Manager of Blue Ocean Group. “We look forward to partnering with the Maas Capital team and its extensive experience and to continue the momentum generated by the portfolio in recent years, all at a time when fundamentals continue to stabilize in the global maritime industry.”

"This acquisition allows the Blue Ocean strategy to continue the growth of its maritime investment portfolio as a leading alternative capital provider to the shipping sector. We are excited to team up with shipping companies that we view as best-in-class partners and look forward to establishing new partnerships with other leaders in the space,” said Omer Donnerstein, Managing Director of EnTrust Global and Investment Analyst for Blue Ocean.

“We are extremely pleased to partner with EnTrust and look forward to continuing to manage and expand the business. This marks a new and exciting chapter in the development of Maas Capital as we expand existing investments, bring on new partners and venture into new markets. A special thanks also goes out to our existing partners, team and stakeholders for their patience and support in this process,” said Mark Ras, Head of Maas Capital.

Since its inception the Blue Ocean strategy has raised $2.6 billion.

EnTrust was represented by Watson Farley & Williams (London) and NautaDutilh (Amsterdam).

About EnTrust Global
EnTrust Global is a leading alternative asset management firm with approximately $19.7 billion in total assets.* Co-founded in 1997 by Chairman and CEO Gregg S. Hymowitz, the firm manages assets for over 500 institutional investors representing 48 countries and has approximately $11 billion in customized strategic partnerships. EnTrust Global offers a diverse range of alternative investment opportunities across strategies, including private debt and real assets as well as opportunistic co-investments and direct investments. EnTrust Global has 10 offices worldwide and is headquartered in New York and London.

*As of June 30, 2021. Based on estimates and includes assets under advisement and mandates awarded but not yet funded.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
EnTrust Global
Hiltzik Strategies
Meghan Kilkenny
EnTrust@hstrategies.com
+1 (212) 792-9338

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 10:05:00 EET | Press release

Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio

SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 10:00:00 EET | Press release

SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive long-term growth. “We are thrilled to welcome Oliver to SkySparc’s leadership team,” said Jo

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 09:23:00 EET | Press release

Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline infusion preparation, reduce healthcare professionals’ workload, and support hospital operational efficiency.3 The Remsima™ IV liquid formulation is approved in the EU for all indications of IV infliximab, matching the approved uses of all existing IV infliximab powder formulations, including rheumatoid arthritis (RA), adult and pediatric Crohn’s disease (CD), ulcerative colitis (UC), pediatric UC, ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis (PsO).1 The comparability between lyophilized powder formulation and the liquid formulation of IV infliximab has been established through comprehensive chemistry, manufacturing, and controls data.2 The stability of the liquid formulation of I

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 09:00:00 EET | Press release

Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the highly respected JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 years, from 2004 through 2024. Debiopharm is now transitioning its historic award into the IDEAL Japan initiative aiming to accelerate preclinical scientific research that could give rise to new treatments for cancer patients. “Our vision is to collaborate to find a cure for cancer,”explained Thierry Mauvernay, President of Debiopharm. “We believe that our ongoing Swiss-Japanese connection needs to evolve and catalyze the trans

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 08:00:00 EET | Press release

Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/ Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio. Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings toget

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye